Pharvaris BV (PHVS NASDAQ) stock market data APIs
$36.3203
-1.05(-2.9%)
as of August 18, 2026
Try our APIs with
free plan!
Pharvaris BV Financial Data Overview
Price chart is built with
Anychart
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Prev. Close
36.3203
Open
35.266
High
36.4005
Low
34.9566
52 wk Range
20.65-36.93
Market Cap
2 480 M
Shares Outstanding
70 205 K
EPS
-0.81
Beta
-2.328
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Pharvaris BV (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at €19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only €19.99
TRY NOW
Get Pharvaris BV data using free add-ons & libraries
Get Pharvaris BV Fundamental Data
Pharvaris BV Fundamental data includes:
- Net Revenue:
- EBITDA: -182 166 128
- Earnings Per Share: -3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
€
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-12
- EPS/Forecast: -0.74
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Pharvaris BV News
New
Claude AI’s Newest Stock Picks Are Also Hedge Fund Favorites: One Breakout Biotech, One AI Chip Bet
Note: the trade details cited in this article come from The Claude Portfolio account on X, a third-party account not affiliated with Anthropic. It tracks how different AI models would trade if given a...
After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over?
Key Points Schikan sold 37,600 shares over June 29, 2026 and June 30, 2026, generating ~ $1.33 million in gross proceeds based on a weighted average price of around $35.41 per share. This transaction...
After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over?
Johannes Gerardus Christiaan Petrus Schikan, Director, reported the sale of 37,600 shares of Pharvaris N.V. (NASDAQ:PHVS) in open-market transactions valued at approximately $1.33 million, according t...
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedemaExplains the scientific foundation for targetin...
Get Pharvaris BV fresh news feed via Financial News API
Corporate Events Calendar & News package for
€19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only €19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
€99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
